Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2023

Apr 3, 2023

32973_dirs_2023-04-03_7d980729-033d-4d9d-9782-f4d87c719a37.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2023-03-27

Reporting Person: Brakewood Harold Eugene (Chief Business Officer)